← All trials
NCT05497674
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 21, 2022
- Primary completion
- Jul 20, 2022
- Completion date
- Aug 1, 2022
- First posted
- Aug 11, 2022
- Last posted
- Aug 11, 2022
- Enrollment
- 28
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sunshine Lake Pharma Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.